Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | AQP1 | P29972 | 1/20 | 0.32 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.32 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | HRH1 | P35367 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6879262 | 1.00 | TDP1 (0.34) | TDP1ALDH1A1TSHRKDM4ESMN1; SMN2 | |
| SCHEMBL6079008 | 0.87 | ALDH1A1 (0.36) | TDP1ALDH1A1TSHRMAPTL3MBTL1 | |
| SCHEMBL6077258 | 0.87 | ALDH1A1 (0.36) | TDP1ALDH1A1TSHRMAPTL3MBTL1 | |
| SCHEMBL6076662 | 0.86 | MAPT (0.35) | TDP1ALDH1A1TSHRKDM4ESMN1; SMN2 | |
| SCHEMBL6076668 | 0.86 | MAPT (0.35) | TDP1ALDH1A1TSHRKDM4ESMN1; SMN2 | |
| SCHEMBL6077375 | 0.85 | TDP1 (0.36) | TDP1ALDH1A1TSHRKDM4ESMN1; SMN2 | |
| SCHEMBL6077514 | 0.85 | ALDH1A1 (0.38) | TDP1ALDH1A1TSHRSMN1; SMN2MAPT | |
| SCHEMBL6077512 | 0.85 | ALDH1A1 (0.38) | TDP1ALDH1A1TSHRSMN1; SMN2MAPT | |
| SCHEMBL6077270 | 0.84 | ALDH1A1 (0.34) | TDP1ALDH1A1TSHRMAPTKMT2A | |
| SCHEMBL6077511 | 0.84 | TDP1 (0.35) | TDP1ALDH1A1TSHRSMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6777440-B2 | HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2004-08-17 | — | — | US | disclosed |
| US-20030176495-A1 | HIV Integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2003-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030176495-A1 | HIV Integrase inhibitors | MAPT, RIF1, HPRT1 | TDP1 10/4885ALDH1A1 976/4885TSHR 4530/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.